{
  "ticker": "IBX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02970300",
  "id": "02970300",
  "pages": 8,
  "price_sensitive": false,
  "date": "20250717",
  "time": "1644",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250717/pdf/06lwv172s6c5sr.pdf",
  "summary": "**Director Interest Change Summary (Appendix 3Y):**  \n\n- **Director:** Robert Romeo Proulx  \n  - **Change:** Granted **2,000,000 unlisted options** (exercise price: **$0.012**, expiry **29 May 2030**), vesting in tranches tied to clinical milestones (e.g., Phase 2 study progress).  \n  - **Consideration:** Nil (approved at AGM on **30 May 2025**).  \n\n- **Director:** Brett Mitchell  \n  - **Change:** Granted **2,000,000 unlisted options** (exercise price: **$0.019**, expiry **29 May 2028**), vesting in equal tranches over 2 years.  \n  - **Consideration:** Nil (approved at AGM on **30 May 2025**).  \n\n**Key Implications:**  \n- No immediate dilution (unlisted options), but potential future dilution if exercised.  \n- Vesting conditions align with clinical/regulatory progress.  \n\n**No material trading or capital structure impact identified beyond disclosed option grants.**",
  "usage": {
    "prompt_tokens": 3251,
    "completion_tokens": 226,
    "total_tokens": 3477,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-17T07:30:27.811232"
}